Form 4: Boston Scientific Director Habiger Receives Stock Grants Following Board Appointment

Director David C. Habiger received stock grants from Boston Scientific following his appointment to the Board of Directors.

Summary

• David C. Habiger, a director at Boston Scientific, received two grants of common stock on August 1, 2024.
• The first grant was for 2,155 shares of restricted stock, prorated for the period from his appointment to the 2025 annual meeting, valued at approximately $161,981.
• The second grant was for 1,252 shares of restricted stock in lieu of cash compensation, also prorated for the same period, valued at approximately $94,175.
• These grants are part of the company's non-employee director compensation program and vest fully at the next annual meeting of stockholders.
• Following these transactions, Habiger directly owns 3,547 shares of Boston Scientific common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice for a director, indicating stability and alignment of interests. It's a neutral to slightly positive event.

Positives

• The grants align Habiger's interests with those of the shareholders.
• The use of restricted stock as part of compensation can help retain directors.
• The prorated nature of the grants is a reasonable approach given the timing of his appointment.

Future Outlook

The restricted stock grants vest in full upon the next annual meeting of stockholders.

Industry Context

Director compensation packages often include a mix of cash and equity to align director interests with shareholder value. The use of restricted stock is a common practice.

Comparison to Industry Standards

• Director compensation at Boston Scientific, including equity grants, is likely benchmarked against peer companies in the medical device industry.
• Companies like Medtronic, Abbott, and Stryker also utilize similar compensation structures for their non-employee directors, often involving a mix of cash retainers and equity awards.
• The specific amounts and vesting schedules may vary based on company size, performance, and industry norms.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning the director's interests with the company's long-term success.
• The director benefits from the equity grants, incentivizing their contributions to the company.

Next Steps

• The restricted stock will vest upon the next annual meeting of stockholders.

Key Dates